Tomorrow the Swiss BB Biotech will report its past quarters results. Over the current book year the total revenue will be 151,23 million CHF (consensus estimates). This is rather significant more than 2018's revenue of 5,78 million CHF.
The analysts expect for 2019 a net profit of 480 million CHF. For this year most of the analysts expect a profit per share of 8,33 CHF. The price/earnings-ratio is then 7,29.
Based on the current number of outstanding shares BB Biotech's market capitalization is 3,36 billion CHF. The BB Biotech stock was the past 12 months quite volatile. Since last October the stock is 6 percent lower. This year the stock price moved between 55 and 74 CHF.
Click here for dividend . At 17.30 the stock trades 1,46 percent lower at 60,7 CHF.
Analist.nl Nieuwsdienst: +31 084-0032-842
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.